[1] Lee WH, Fujiwara M.Pharmacometrics of guinea-pig's gallbladder in vitro[J]. Taiwan Yi Xue Hui Za Zhi, 1971, 70:687-696. [2] Lee C, Barnes A, Katz RL.Neuromuscular sensitivity to tubocurarine.A comparison of 10 parameters[J]. Br J Anaesth, 1976, 48:1045-1051. [3] Williams PJ, Ette EI. Pharmacometrics:impacting drug development and pharmacotherapy[M] E.i.Ette and P. J. Williams, Editors. Pharmacometrics:The Science of Quantitative Pharmacology. John Wiley & Sons: Hoboken, 2007: 1-21. [4] Barrett JS.Applying Quantitative Pharmacology in an Academic Translational Research Environment[J]. Aaps J, 2008, In press. [5] Zerhouni E.Medicine. The NIH Roadmap[J]. Science, 2003, 302:63-72. [6] CDER.Innovation and stagnation:Challenge and opportunity on the critical path to new medicinal products[S]. US Food and Drug Administration, 2004. [7] Gieschke R, Reigner BG, Steimer JL.Exploring clinical study design by computer simulation based on pharmacokinetic/pharmacodynamic modelling[J]. Int J Clin Pharmacol Ther, 1997, 35:469-474. [8] Gieschke R, Burger HU, Reigner B, et al. Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients[J]. Br J Clin Pharmacol, 2003, 55:252-263. [9] Bruno R, Vivier N, Vergniol JC, et al. A population pharmacokinetic model for docetaxel (Taxotere):model building and validation[J]. J Pharmacokinet Biopharm, 1996, 24:153-172. [10] Veyat-Follet C, Bruno R, Olivares R, et al, Clinical trial simulation of docetaxel in patients with cancer as a tool for dosage optimization[J]. Clin Pharmacol Ther, 2000, 68: 677-687. [11] Zhang L, Sinha V, Forgue ST, et al.Model-based drug development:the road to quantitative pharmacology[J]. J Pharmacokinet Pharmacodyn, 2006, 33:369-393. [12] Sarkar S, Mitlak BH, Wong M, et al.Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy[J]. J BoneMiner Res, 2002, 17:1-10. [13] Delmas PD, Ensrud KE, Adachi JD, et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis:four-year results from a randomized clinical trial[J]. J Clin Endocrinol Metab, 2002, 87:3609-3617. [14] Noble D, Levin J, Scott W.Biological simulations in drug discovery[J]. Drug Discov Today, 1999, 4:10-16. [15] Lesko LJ, Rowland M, Peck CC, et al.Optimizing the science of drug development:opportunities for better candidate selection and accelerated evaluation in humans[J]. Pharm Res, 2000, 17:1335-1344. [16] Drusano GL, Louie A, Deziel M, et al.The crisis of resistance: identifying drug exposures to suppress amplification of resistant mutant subpopulations[J]. Clin Infect Dis, 2006, 42: 525-532. [17] Hutmacher MM, Mukherjee D, Kowalski KG, et al. Collapsing mechanistic models:an application to dose selection for proof of concept of a selective irreversible antagonist[J]. J Pharmacokinet Pharmacodyn, 2005, 32: 501- 520. [18] Gieschke R, Steimer JL.Pharmacometrics: modelling and simulation tools to improve decision making in clinical drug development[J]. Eur J Drug Metab Pharmacokinet, 2000, 25:49-58. [19] Bortz DM, Nelson PW.Model selection and mixed-effects modeling of HIV infection dynamics[J]. Bull Math Biol,2006, 68:2005-2025. [20] Lindsay R, Pack S, Li Z.Longitudinal progression of fracture prevalence through a population of postmenopausal women with osteoporosis[J]. Osteoporos Int, 2005, 16:306-312. [21] Mostafavi S, Baranzini S, Oksernberg J, et al.Predictive modeling of therapy response in multiple sclerosis using gene expression data[J]. Conf Proc IEEE Eng Med Biol Soc, 2006, 1:5519-5522. [22] Van der Helm-van Mil AH, le Cessie S, van Dongen H,et al. A prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: how to guide individual treatment decisions[J]. Arthritis Rheum, 2007, 56(2):433-440. [23] Anderson JJ, Bolognese JA, Felson DT.Comparison of rheumatoid arthritis clinical trial outcome measures:a simulation study[J]. Arthritis Rheum, 2003, 48(11):3031- 3038. [24] Barton P, Jobanputra P, Wilson J, et al. The use of modeling to evaluate new drugs for patients with a chronic condition:the case of antibodies against tumour necrosis factor in rheumatoid arthritis[J]. Health Technol Assess,2004, 8:iii, 1-91. [25] Barnett J. Directors of pharmacology graduate programs: Pharm Phorum[J]. Mol Interv, 2006, 6:4-7. [26] Lalonde RL, Kowalski KG, Hutmacher MM, et al.Model-based drug development[J]. Clin Pharmacol Ther, 2007, 82:21-32. [27] Grasela TH, Fiedler-Kelly J, Walawander CA, et al. Challenges in the transition to model-based development[J]. Aaps J, 2005, 7:E488-495. [28] Grasela TH, Dement CW, Kolterman OG, et al.Pharmacometrics and the transition to model-based development [J]. Clin Pharmacol Ther, 2007, 82: 137-142. [29] Atkinson AJ Jr, Lalonde RL.Introduction of quantitative methods in pharmacology and clinical pharmacology: a historical overview[J]. Clin Pharmacol Ther, 2007, 82: 3-6. [30] Powell JR, Gobburu JV.Pharmacometrics at FDA:evolution and impact on decisions[J]. Clin Pharmacol Ther, 2007, 82:97-102. [31] Gobburu JV, Marroum PJ.Utilisation of pharmacokineticpharmacodynamic modelling and simulation in regulatory decision-making[J]. Clin Pharmacokinet, 2001, 40:883-892. [32] Zerhouni EA.Translational and clinical science — time for a new vision[J]. N Engl JMed, 2005, 353:1621-1623. [33] Zerhouni EA, Alving B.Clinical and translational science awards:a framework for a national research agenda[J]. Transl Res, 2006, 148: 4-5. [34] Barrett JS. Facilitating compound progression of antiretroviral agents via modeling and simulation[J]. J Neuroimmune Pharmacol, 2007, 2:58-71. [35] Bonate P.Pharmacokinetic-pharmacodynamic modeling and simulation[M]. New York:Springer, 2006. [36] Holford N, Karlsson MO.Time for quantitative clinical pharmacology: a proposal for a pharmacometrics curriculum[J]. Clin Pharmacol Ther, 2007, 82: 103-105. [37] Lertora JJ, Atkinson AJ Jr. Clinical pharmacology education and training at the National Institutes of Health[J]. Clin Pharmacol Ther, 2007, 81:907-909. [38] Collier AC. The role of pharmacology in medical teaching [J]. Hawaii Med J, 2007, 66:135-136. [39] Mehvar R.Development and application of an on-line module for teaching bayesian forecasting principles in a clinical pharmacokinetics course[J]. Am J Pharm Educ, 2000, 64:121-125. [40] Maxwell SR, McQueen DS, Ellaway R.eDrug: a dynamic interactive electronic drug formulary for medical students [J]. Br J Clin Pharmacol, 2006, 62: 673-681. [41] Hughes DA, Walley T.Economic evaluations during early(phase II)drug development:a role for clinical trial simulations[J] ? Pharmacoeconomics, 2001, 19:1069-1077. [42] Sheiner LB.Learning versus confirming in clinical drug development[J]. Clin Pharmacol Ther, 1997, 61:275-291. [43] Bhattaram VA, Booth BP, Ramchandani RP, et al.Impact of pharmacometrics on drug approval and labeling decisions:a survey of 42 new drug applications[J]. Aaps J,2005, 7:E503-512. [44] Bhattaram VA, Bonapace C, Chilukuri DM, et al.Impact of pharmacometric reviews on new drug approval and labeling decisions — a survey of 31 new drug applications submitted between 2005 and 2006[J]. Clin Pharmacol Ther, 2007, 81:213-221. |